The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: A randomized clinical study
- 1 June 2005
- journal article
- clinical trial
- Published by Wiley in Clinical Cardiology
- Vol. 28 (6) , 298-302
- https://doi.org/10.1002/clc.4960280609
Abstract
Background: Prolongation of P‐wave times and increase of P‐wave dispersion (PWD) were shown to be independent predictors of atrial fibrillation (AF). Angiotensin II receptor blockers (AARBs) and angiotensin‐converting enzyme inhibitors (ACEIs) have beneficial effects on atrial conduction times. However, there are not enough data about the comparative effects of those drugs onPWD. Hypothesis: We aimed to compare the effects of telmisartan and ramipril on PWD after 6‐month treatment in hypertensive patients. Methods: In all, 100 newly diagnosed hypertensive patients were enrolled in the study and were randomly assigned to two groups. Group 1 and Group 2 each consisted of 50 patients, taking daily doses of 80 mg telmisartan and 10 mg ramipril, respectively. Twelve‐lead surface electrocardiograms (ECG) were recorded from all patients before and after 6‐month drug therapy. The P‐wave duration (Pdur) measurements were calculated from the 12‐lead surface ECG. Results: When pretreatment PWD and P maximum values were compared with post‐treatment values, a statistically significant decrease was found in both groups after 6 months (Group 1 and 2; p < 0.001 for PWD and Pmaximum). P‐wave dispersion and Pmaximum values after treatment in Group 1 were statistically significantly lower than those in Group 2 after the 6‐month treatment period (p = 0.01 for PWD; p = 0.008 for Pmaximum). Conclusions: Telmisartan has a much greater lowering effect on PWD and Pmaximum values than ramipril. This finding may be important in the prevention of AF in hypertensive patients.Keywords
This publication has 21 references indexed in Scilit:
- Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trialsAmerican Heart Journal, 2004
- Circadian variation of arrhythmia onset patterns in patients with persistent atrial fibrillationAmerican Heart Journal, 2003
- Editorial: Recent hypertension guidelines: JNC-7 and 2003 ESH/ESCBlood Pressure, 2003
- Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial FibrillationCirculation, 2002
- Effect of left atrial size and function on P‐wave dispersion: A study in patients with paroxysmal atrial fibrillationClinical Cardiology, 2001
- Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive PatientsCirculation, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Overexpression of Bax Protein and Enhanced Apoptosis in the Left Ventricle of Spontaneously Hypertensive RatsHypertension, 1998
- TelmisartanDrugs, 1998
- Evidence-Based Health Policy—Lessons from the Global Burden of Disease StudyScience, 1996